Who is sponsoring NCT06029764?

NCT06029764 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT06029764?

Interventions in NCT06029764: extended one-level interbody fusion.

What condition does NCT06029764 study?

NCT06029764 studies Adjacent Segment Degeneration.

Is NCT06029764 still recruiting?

NCT06029764 is currently recruiting now. Last updated 8 September 2023.

Last reviewed 2023-09-08 · How we verify

NCT06029764

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Extended One-level Interbody Fusion for Adjacent Vacuum Phenomenon in Lumbar Degenerative Disc Disease

Recruiting now NA Last updated 8 September 2023

What this trial tests

NA trial testing extended one-level interbody fusion in Adjacent Segment Degeneration in 126 participants. Currently enrolling.

Timeline

1 February 2023

Primary endpoint
1 January 2028

1 January 2029

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	126
Start date	1 February 2023
Primary completion	1 January 2028
Estimated completion	1 January 2029
Sites	1 location across China

Drugs / interventions tested

extended one-level interbody fusion

Conditions studied

Adjacent Segment Degeneration — all drugs for Adjacent Segment Degeneration →

Sponsor

Xuanwu Hospital, Beijing

Who can join

Adults 18 to 60, any sex, with Adjacent Segment Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study was to validate the clinical effectiveness of interbody fusion with a one-segment extension for the treatment of adjacent segmental space discs in the surgical treatment of lumbar degeneration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Adjacent Segment Degeneration

Currently open trials in the same condition.

NCT07396051 — Rehabilitation Exercise Against Complications in High-risk Elderly After Lumbar Fusion(REACH) · NA · recruiting

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06029764 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 8 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06029764.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing